Advertisement

What medications can help treat phenylketonuria?

In addition to a low-phenylalanine diet, treatment for PKU may include one of these medications.

Updated on December 16, 2025

Phenylketonuria (PKU) is a rare genetic disorder that disrupts the body’s ability to metabolize a substance called phenylalanine.

Phenylalanine is one of the essential amino acids. Essential amino acids are nutrients that the body cannot produce on its own and must be consumed in food. Phenylalanine is found in protein-containing foods and plays an important role in the production of the brain’s neurotransmitters, or chemical messengers.

When a person has PKU, the body cannot metabolize phenylalanine. As a result, high amounts of this amino acid build up in the blood. This can have a toxic effect on the body and cause damage to the brain. PKU can cause cognitive disability, developmental delays, seizures, and problems with mood and behavior, especially when untreated.

Are there different types of PKU?

There are several different forms of PKU, which vary in severity. Some forms are severe and carry a significant risk of brain damage and complications. Other forms are less severe, and the risk of brain damage and complications is lower.

Classic PKU

Another way to think about PKU is in terms of PAH deficiency. PAH is phenylalanine hydroxylase, an enzyme that the body needs to metabolize phenylalanine. This deficiency occurs when the genes that contain the instructions for producing this enzyme do not function normally. The genetic variations that cause PKU are inherited from a person’s biological parents.

Classic PKU is the most severe form of the disease. With classic PKU, the body produces very little PAH or no PAH at all. This type has the most significant risk of brain damage and complications.

Variant PKU and non-PKU hyperphenylalaninemia

With less severe types, there is more functioning PAH. Less severe types may be categorized as mild or moderate PKU or variant PKU. There is also non-PKU hyperphenylalaninemia, which is considered a mild form of the disease. However, non-PKU hyperphenylalaninemia can also cause reduced cognitive function, behavioral disorders, and developmental disorders.

Medications that help treat PKU

There are also medications that can help lower phenylalanine levels in some cases of PKU. These medications can be used alongside diet but cannot fully replace diet.

Medications for children and adults with PKU

Several medications are approved for children 1 month and older and adults. These medications work by increasing enzyme activity. More specifically, they act on a substance that activates PAH, called BH4.

For some people with PKU, increasing the amount of BH4 will increase the activity of PAH, which helps the body metabolize more phenylalanine and reduce the amount of phenylalanine in the blood.

There are two types of medications that can increase BH4 in people with PKU.

  • A medication that contains a synthetic version of the enzyme BH4. This increases the amount of BH4 by adding more BH4 into the body. People with more mild forms of PKU are generally more responsive to this treatment, people with classic PKU are typically less responsive.
  • A medication that contains a substance called sepiapterin. Sepiapterin is a precursor to the enzyme BH4. Increasing the amount of this precursor helps the body produce more BH4. This type of medication has been shown to be effective for all types of PKU.

To determine if these medications can be effective, a healthcare team may perform something called a loading test. During a loading test, a person will take a medication for a period of time. Bloodwork will be used to measure phenylalanine levels and check for a response.

Enzyme injections

Another medication option is another type of enzyme substitute that reduces blood phenylalanine levels by converting phenylalanine into two other substances, ammonia and trans-cinnamic acid. Ammonia can be metabolized by the liver. Trans-cinnamic acid is excreted by urine.

This therapy is administered with subcutaneous injections. It is approved for adults with uncontrolled phenylalanine levels. Due to a risk of life-threatening allergic reactions, it is only available through a restricted distribution program and people prescribed this therapy must carry an automatic epinephrine injection device.

Article sources open article sources

William L. Stone, Hajira Basit, and Evan Los. Phenylketonuria. StatPearls. August 8, 2023.
Mayo Clinic. Phenylketonuria (PKU). Accessed December 3, 2025.
MedlinePlus. Amino Acids. Accessed December 3, 2025.
Cleveland Clinic. Amino Acids. Accessed December 3, 2025.
Children's Hospital of Philadelphia. Phenylketonuria (PKU). Accessed December 3, 2025.
Eunice Kennedy Shriver National Institute of Child Health and Human Development. What are common treatments for phenylketonuria (PKU)? Accessed December 3, 2025.
Eunice Kennedy Shriver National Institute of Child Health and Human Development. Phenylketonuria (PKU). Accessed December 3, 2025.
MedlinePlus Genetics. Phenylketonuria. Accessed December 3, 2025.
Georgianne Arnold and Jerry Vockley. Phenylalanine Hydroxylase Deficiency. GeneReviews. November 20, 2025.
Genetic and Rare Disease Information Center. Mild phenylketonuria. Accessed December 3, 2025.
Health Resources & Services Administration. Non-PKU Hyperphenylalaninemia. Accessed December 3, 2025.
Ibrahim Elsharkawi. Phenylketonuria (PKU). Medscape. August 18, 2025.
National Library of Medicine DailyMed. SEPHIENCE- sepiapterin powder. Accessed December 3, 2025.
Tuany Eichwald, Lucila de Bortoli da Silva, et al. Tetrahydrobiopterin: Beyond Its Traditional Role as a Cofactor. Antioxidants, 2023. Vol. 12, No. 5.
Jariya Upadia, Kea Crivelly, et al. Maximal dietary responsiveness after tetrahydrobiopterin (BH4) in 19 phenylalanine hydroxylase deficiency patients: What super-responders can expect. Molecular Genetics and Metabolism Reports, 2024. Vol. 38.
Drugs and Lactation Database (LactMed). Sapropterin. May 15, 2024.
Drago Bratkovic, Lali Margvelashvili, et al. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study. Metabolism, 2022. Vol. 128.
Ania C. Muntau, Nicola Longo, et al. Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 2024. Vol. 404.
Manuela Lo Bianco, Roberta Leonardi, et al. Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring. Nutrients, 2025. Vol. 17, No. 17.
Tasmina Hydery and Valerie Azzopardi Coppenrath. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria. Drug Target Insights. Jun 21, 2019.
MedlinePlus. Pegvaliase-pqpz Injection. Accessed December 3, 2025.

Featured Content

article

Working with a pediatric PKU healthcare team

An overview of the pediatric healthcare providers that treat PKU and questions to ask your child’s healthcare team.
article

An overview of treatment for phenylketonuria

Why a low-phenylalanine diet remains critical to treatment for PKU and how treatment options have expanded.
article

PKU: Strategies for following a low phenylalanine diet

Adhering to a low-phenylalanine diet is one of the most challenging aspects of managing phenylketonuria (PKU).